Does the media refer more to BBOT or NVAX?

In the previous week, Novavax had 2 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 18 mentions for Novavax and 16 mentions for BridgeBio Oncology Therapeutics. Novavax's average media sentiment score of 0.50 beat BridgeBio Oncology Therapeutics' score of 0.10 indicating that Novavax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Oncology Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Novavax 6 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has better earnings and valuation, BCAX or BBOT?

Bicara Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bicara Therapeutics N/A N/A -$137.95M -$3.10 N/A BridgeBio Oncology Therapeutics N/A N/A -$134.04M -$2.76 N/A

Is BCAX or BBOT more profitable?

Bicara Therapeutics' return on equity of -41.49% beat BridgeBio Oncology Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Bicara Therapeutics N/A -41.49% -38.59% BridgeBio Oncology Therapeutics N/A -46.90% -42.17%

Does the media favor BCAX or BBOT?

In the previous week, BridgeBio Oncology Therapeutics had 11 more articles in the media than Bicara Therapeutics. MarketBeat recorded 16 mentions for BridgeBio Oncology Therapeutics and 5 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.92 beat BridgeBio Oncology Therapeutics' score of 0.10 indicating that Bicara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Oncology Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation & earnings, BBOT or AAPG?

BridgeBio Oncology Therapeutics has higher earnings, but lower revenue than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BridgeBio Oncology Therapeutics N/A N/A -$134.04M -$2.76 N/A Ascentage Pharma Group International $82.10M 17.62 -$177.71M N/A N/A

Is BBOT or AAPG more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat BridgeBio Oncology Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets BridgeBio Oncology Therapeutics N/A -46.90% -42.17% Ascentage Pharma Group International N/A N/A N/A

Which has preferable earnings & valuation, AVBP or BBOT?

ArriVent BioPharma is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ArriVent BioPharma N/A N/A -$166.31M -$3.62 N/A BridgeBio Oncology Therapeutics N/A N/A -$134.04M -$2.76 N/A

Is AVBP or BBOT more profitable?

BridgeBio Oncology Therapeutics' return on equity of -46.90% beat ArriVent BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets ArriVent BioPharma N/A -50.26% -46.66% BridgeBio Oncology Therapeutics N/A -46.90% -42.17%

BridgeBio Oncology Therapeutics (BBOT) Competitors

$4.81 -0.07 (-1.35%)

As of 02:09 PM Eastern

Compare

BBOT vs. NVAX, BCAX, AAPG, AVBP, and RARE

Should you buy BridgeBio Oncology Therapeutics stock or one of its competitors? BridgeBio Oncology Therapeutics's main competitors and comparable companies include Novavax (NVAX), Bicara Therapeutics (BCAX), Ascentage Pharma Group International (AAPG), ArriVent BioPharma (AVBP), and Ultragenyx Pharmaceutical (RARE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BridgeBio Oncology Therapeutics compare to Novavax?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Novavax (NASDAQ:NVAX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

In the previous week, Novavax had 2 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 18 mentions for Novavax and 16 mentions for BridgeBio Oncology Therapeutics. Novavax's average media sentiment score of 0.50 beat BridgeBio Oncology Therapeutics' score of 0.10 indicating that Novavax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Oncology Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral
Novavax	6 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Novavax has higher revenue and earnings than BridgeBio Oncology Therapeutics. Novavax is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A
Novavax	$1.12B	1.37	$440.30M	-$1.52	N/A

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%
Novavax	-59.87%	-14.82%	-13.35%

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Comparatively, 1.6% of Novavax shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BridgeBio Oncology Therapeutics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Novavax has a beta of 2.45, suggesting that its stock price is 145% more volatile than the broader market.

BridgeBio Oncology Therapeutics currently has a consensus target price of $22.88, suggesting a potential upside of 366.93%. Novavax has a consensus target price of $14.00, suggesting a potential upside of 50.30%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Novavax beats BridgeBio Oncology Therapeutics on 8 of the 15 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Bicara Therapeutics?

Bicara Therapeutics (NASDAQ:BCAX) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. 13.8% of Bicara Therapeutics shares are owned by company insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, BridgeBio Oncology Therapeutics had 11 more articles in the media than Bicara Therapeutics. MarketBeat recorded 16 mentions for BridgeBio Oncology Therapeutics and 5 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.92 beat BridgeBio Oncology Therapeutics' score of 0.10 indicating that Bicara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Oncology Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral

Bicara Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A

Bicara Therapeutics presently has a consensus price target of $32.64, suggesting a potential upside of 44.83%. BridgeBio Oncology Therapeutics has a consensus price target of $22.88, suggesting a potential upside of 366.93%. Given BridgeBio Oncology Therapeutics' higher probable upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Bicara Therapeutics' return on equity of -41.49% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-41.49%	-38.59%
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%

Bicara Therapeutics has a beta of -0.82, meaning that its stock price is 182% less volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

Summary

BridgeBio Oncology Therapeutics beats Bicara Therapeutics on 8 of the 12 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Ascentage Pharma Group International?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Ascentage Pharma Group International (NASDAQ:AAPG) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Ascentage Pharma Group International's return on equity of 0.00% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%
Ascentage Pharma Group International	N/A	N/A	N/A

BridgeBio Oncology Therapeutics presently has a consensus target price of $22.88, indicating a potential upside of 366.93%. Ascentage Pharma Group International has a consensus target price of $46.43, indicating a potential upside of 199.73%. Given BridgeBio Oncology Therapeutics' higher probable upside, equities research analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Ascentage Pharma Group International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BridgeBio Oncology Therapeutics has higher earnings, but lower revenue than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A
Ascentage Pharma Group International	$82.10M	17.62	-$177.71M	N/A	N/A

In the previous week, BridgeBio Oncology Therapeutics had 14 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 16 mentions for BridgeBio Oncology Therapeutics and 2 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 0.45 beat BridgeBio Oncology Therapeutics' score of 0.10 indicating that Ascentage Pharma Group International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Oncology Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ascentage Pharma Group International	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BridgeBio Oncology Therapeutics has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market.

Summary

BridgeBio Oncology Therapeutics beats Ascentage Pharma Group International on 7 of the 13 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

BridgeBio Oncology Therapeutics' return on equity of -46.90% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-50.26%	-46.66%
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%

ArriVent BioPharma is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A

In the previous week, BridgeBio Oncology Therapeutics had 15 more articles in the media than ArriVent BioPharma. MarketBeat recorded 16 mentions for BridgeBio Oncology Therapeutics and 1 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.87 beat BridgeBio Oncology Therapeutics' score of 0.10 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
ArriVent BioPharma	Very Positive
BridgeBio Oncology Therapeutics	Neutral

ArriVent BioPharma has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

ArriVent BioPharma presently has a consensus price target of $44.86, suggesting a potential upside of 62.67%. BridgeBio Oncology Therapeutics has a consensus price target of $22.88, suggesting a potential upside of 366.93%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by company insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

BridgeBio Oncology Therapeutics beats ArriVent BioPharma on 11 of the 13 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Ultragenyx Pharmaceutical has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. BridgeBio Oncology Therapeutics' return on equity of -46.90% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ultragenyx Pharmaceutical presently has a consensus price target of $36.63, suggesting a potential upside of 182.41%. BridgeBio Oncology Therapeutics has a consensus price target of $22.88, suggesting a potential upside of 366.93%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	9 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.52
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

BridgeBio Oncology Therapeutics has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	1.90	-$575M	-$5.84	N/A
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A

In the previous week, BridgeBio Oncology Therapeutics had 8 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 16 mentions for BridgeBio Oncology Therapeutics and 8 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.30 beat BridgeBio Oncology Therapeutics' score of 0.10 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
BridgeBio Oncology Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

BridgeBio Oncology Therapeutics beats Ultragenyx Pharmaceutical on 11 of the 16 factors compared between the two stocks.

Get BridgeBio Oncology Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBOT vs. The Competition

Export

Metric	BridgeBio Oncology Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$392.03M	$3.86B	$7.21B	$14.99B
Dividend Yield	N/A	3.65%	2.57%	11.71%
P/E Ratio	-1.77	14.53	273.61	25.47
Price / Sales	N/A	1,419.88	698.20	113.08
Price / Cash	N/A	108.94	77.71	51.48
Price / Book	0.95	15.22	10.40	6.34
Net Income	-$134.04M	-$22.78M	$3.49B	$358.32M
7 Day Performance	-27.53%	-0.50%	-0.12%	0.29%
1 Month Performance	-45.93%	0.63%	-0.03%	-3.10%
1 Year Performance	N/A	39.38%	19.22%	6.52%

BridgeBio Oncology Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBOT BridgeBio Oncology Therapeutics	3.0476 of 5 stars	$4.81 -1.4%	$22.88 +375.2%	N/A	$385.94M	N/A	N/A	88
NVAX Novavax	2.2582 of 5 stars	$9.42 +1.3%	$14.00 +48.6%	+14.2%	$1.55B	$1.12B	N/A	1,990
BCAX Bicara Therapeutics	2.1981 of 5 stars	$22.81 -1.3%	$32.64 +43.1%	+99.2%	$1.51B	N/A	N/A	32	Positive News
AAPG Ascentage Pharma Group International	3.0959 of 5 stars	$16.10 -3.4%	$46.43 +188.4%	-58.8%	$1.50B	$82.10M	N/A	600	Gap Down
AVBP ArriVent BioPharma	2.4625 of 5 stars	$29.00 +1.0%	$44.86 +54.7%	+47.6%	$1.43B	N/A	N/A	40	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBOT) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BridgeBio Oncology Therapeutics (BBOT) Competitors

BBOT vs. NVAX, BCAX, AAPG, AVBP, and RARE

How does BridgeBio Oncology Therapeutics compare to Novavax?

Summary

How does BridgeBio Oncology Therapeutics compare to Bicara Therapeutics?

Summary

How does BridgeBio Oncology Therapeutics compare to Ascentage Pharma Group International?

Summary

How does BridgeBio Oncology Therapeutics compare to ArriVent BioPharma?

Summary

How does BridgeBio Oncology Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBOT vs. The Competition

BridgeBio Oncology Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BridgeBio Oncology Therapeutics (BBOT) Competitors

BBOT vs. NVAX, BCAX, AAPG, AVBP, and RARE

How does BridgeBio Oncology Therapeutics compare to Novavax?

Does the media refer more to BBOT or NVAX?

Which has better earnings and valuation, BBOT or NVAX?

Is BBOT or NVAX more profitable?

Do institutionals and insiders hold more shares of BBOT or NVAX?

Which has more volatility & risk, BBOT or NVAX?

Do analysts prefer BBOT or NVAX?

Summary

How does BridgeBio Oncology Therapeutics compare to Bicara Therapeutics?

Do institutionals & insiders hold more shares of BCAX or BBOT?

Does the media favor BCAX or BBOT?

Which has better earnings and valuation, BCAX or BBOT?

Do analysts rate BCAX or BBOT?

Is BCAX or BBOT more profitable?

Which has more risk and volatility, BCAX or BBOT?

Summary

How does BridgeBio Oncology Therapeutics compare to Ascentage Pharma Group International?

Is BBOT or AAPG more profitable?

Do analysts recommend BBOT or AAPG?

Do institutionals & insiders have more ownership in BBOT or AAPG?

Which has higher valuation & earnings, BBOT or AAPG?

Does the media refer more to BBOT or AAPG?

Which has more risk & volatility, BBOT or AAPG?

Summary

How does BridgeBio Oncology Therapeutics compare to ArriVent BioPharma?

Is AVBP or BBOT more profitable?

Which has preferable earnings & valuation, AVBP or BBOT?

Does the media prefer AVBP or BBOT?

Which has more risk and volatility, AVBP or BBOT?

Do analysts prefer AVBP or BBOT?

Do insiders and institutionals believe in AVBP or BBOT?

Summary

How does BridgeBio Oncology Therapeutics compare to Ultragenyx Pharmaceutical?

Which has more volatility & risk, RARE or BBOT?

Is RARE or BBOT more profitable?

Do institutionals & insiders hold more shares of RARE or BBOT?

Do analysts recommend RARE or BBOT?

Which has better valuation & earnings, RARE or BBOT?

Does the media prefer RARE or BBOT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBOT vs. The Competition

BridgeBio Oncology Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools